AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer by Vandana Singh Benzinga Editor Follow ...

AstraZeneca Late in the afternoon on the first Friday of April, Andrew Monticelli, an oncologist at Rocky Mountain Cancer Centers, got a phone call from Jeff Sharman, the medical director of ...

Calquence, which was approved in the U.S. for chronic lymphocytic leukemia patients in November, was the only product of Acerta, which was acquired by AstraZeneca in a $7 billion deal in 2016.

RELATED: AstraZeneca's Calquence preps for Imbruvica showdown with phase 3 CLL win The British drugmaker is keeping the details under wraps for now; they’ll debut at a future medical meeting.

The British drugmaker gained access to Calquence in 2015, thanks to a $4 billion-plus deal with developer Acerta. And to that payoff, AstraZeneca isn’t stopping with MCL.

FDA fully approves AstraZeneca's Calquence combo therapy, reducing MCL progression/death risk by 27% in Phase 3 ECHO trial. Median progression-free survival extended to 66.4 months with Calquence ...

AstraZeneca has built a strong oncology portfolio, which includes Tagrisso, Imfinzi, Lynparza, Iressa, Calquence and other legacy drugs. Sales of this segment were 37% of the company’s total ...